Vaccines*
Vaccine | Type | Route |
|---|---|---|
Anthrax vaccine (see Anthrax vaccine (seeCDC) | Inactivated bacteria | IM |
Bacille Calmette-Guérin vaccine for Bacille Calmette-Guérin vaccine fortuberculosis (see CDC) | Live Mycobacteria bovis | Intradermal |
Chikungunya vaccines (see CDC) | Live-attenuated vaccine derived from the LR2006 OPY1 strain of chikungunya virus | IM |
Recombinant VLP mimicking chikungunya virus antigen from Senegal strain 37997 | IM | |
Cholera vaccine (see Cholera vaccine (seeCDC) | Live-attenuated vaccine | Oral |
SARS-CoV-2 virus (COVID-19) mRNA vaccines (see SARS-CoV-2 virus (COVID-19) mRNA vaccines (seeCDC) | Viral mRNA | IM |
SARS-CoV-2 virus (COVID-19) recombinant spike protein nanoparticle vaccine (see SARS-CoV-2 virus (COVID-19) recombinant spike protein nanoparticle vaccine (seeCDC) | Adjuvanted containing a recombinant form of the SARS-CoV-2 spike protein | IM‡ |
Dengue tetravalent vaccine (see Dengue tetravalent vaccine (seeCDC and see WHO) | Tetravalent, live-attenuated vaccine | Subcutaneous |
Diphtheria toxoid/tetanus toxoid/acellular pertussis/Haemophilus influenzae type b conjugate vaccine/inactivated poliovirus vaccine (DTaP-IPV-Hib) (see Diphtheria toxoid/tetanus toxoid/acellular pertussis/Haemophilus influenzae type b conjugate vaccine/inactivated poliovirus vaccine (DTaP-IPV-Hib) (seeCDC) | Toxoids, inactivated bacteria, inactivated poliovirus, and bacterial polysaccharide conjugated to protein | IM |
Diphtheria toxoid/hepatitis B vaccine/inactivated poliovirus vaccine (DTaP-HepB-IPV) (see Diphtheria toxoid/hepatitis B vaccine/inactivated poliovirus vaccine (DTaP-HepB-IPV) (seeCDC) | Toxoids, recombinant viral antigen, and inactivated poliovirus | IM |
Diphtheria toxoid/tetanus toxoid/acellular pertussis/inactivated poliovirus vaccine (see CDC) (DTaP-IPV) | Toxoids, inactivated bacteria, and inactivated poliovirus | IM |
Diphtheria/tetanus toxoids/pertussis vaccine (DTaP) (see Diphtheria/tetanus toxoids/pertussis vaccine (DTaP) (seeCDC) | Toxoids and inactivated bacterial components | IM |
Diphtheria toxoid/tetanus toxoid adsorbed, DT, Td (see Diphtheria toxoid/tetanus toxoid adsorbed, DT, Td (seeCDC)¶ | Inactivated toxins (toxoids) | IM‡ |
Ebola (rVSV-ZEBOV) (see CDC) | Live-attenuated recombinant vaccine (protects against only the Zaire ebolavirus species) | IM |
Haemophilus influenzae type b conjugate vaccine (Hib) (see CDC) | Bacterial polysaccharide conjugated to protein | IM |
Hepatitis A vaccine (HepA) (see Hepatitis A vaccine (HepA) (seeCDC) | Inactivated virus | IM |
Hepatitis B vaccine (HepB) (see Hepatitis B vaccine (HepB) (seeCDC) | Recombinant viral antigen | IM |
Hepatitis A vaccine/hepatitis B (HepA/HepB) vaccine (see Hepatitis A vaccine/hepatitis B (HepA/HepB) vaccine (seeCDC) | Inactivated virus plus recombinant viral antigens | IM |
Human papillomavirus vaccines (see CDC) | VLPs from L1 major capsid protein of HPV:
| IM |
Injected influenza vaccines (see CDC) | Inactivated A and B viruses or viral components | IM or intradermal |
Intranasal influenza vaccine (LAIV) (see Intranasal influenza vaccine (LAIV) (seeCDC) | Live influenza A and B viruses | Intranasal |
Japanese encephalitis virus vaccine (see Japanese encephalitis virus vaccine (seeCDC) | Inactivated virus | Subcutaneous or IM |
Recombinant protein subunit; RTS,S antigen of circumsporozoite protein (CSP) of Plasmodium falciparum with hepatitis B surface antigen (HBsAg), adjuvanted with AS01 | IM‡ | |
Recombinant protein subunit; R21 antigen of CSP of P. falciparum with HBsAg, adjuvanted with Matrix-M | IM‡ | |
Measles/mumps/rubella vaccines (MMR) (see Measles/mumps/rubella vaccines (MMR) (seeCDC) | Live virus | Subcutaneous or IM |
Measles virus/mumps virus/rubella virus/varicella virus vaccine (MMRV) (see Measles virus/mumps virus/rubella virus/varicella virus vaccine (MMRV) (seeCDC) | Live virus | Subcutaneous or IM |
Meningococcal conjugate vaccine (4 strain) (MenACWY-CRM or MenACWY-TT) (see CDC) | Bacterial polysaccharides of serogroups A, C, W-135, and Y | IM |
Meningococcal group B vaccine (4 strain) (MenB-FHbp) and meningococcal group B vaccine (3 strain) (MenB-4C) (see Meningococcal group B vaccine (4 strain) (MenB-FHbp) and meningococcal group B vaccine (3 strain) (MenB-4C) (seeCDC) | Recombinant vaccines composed of 2 antigens (FHbp) | IM |
Meningococcal conjugate vaccine (5 strain) (MenACWY-TT/MenB-FHbp) (see CDC) | Conjugate vaccine; serogroups A, B, C, W-135, and Y polysaccharides individually conjugated to TT, and 2 recombinant lipidated factor H–binding protein (FHbp) serogroup B variants | IM |
Meningococcal groups A, B, C, W, and Y vaccine (5 strain) (MenACWY-CRM/MenB-FHbp) (see CDC) | Oligosaccharides of serogroups A, C, Y, and W-135 conjugated to diphtheria CRM197 protein and recombinant lipidated FHbp serogroup B variant | IM |
Mpox (monkeypox) vaccine (smallpox and monkeypox vaccine) (see CDC) | Live, nonreplicating vaccinia virus | Subcutaneous, or intradermal via multiple puncture device |
Pneumococcal vaccine, conjugate (PCV15) (see Pneumococcal vaccine, conjugate (PCV15) (seeCDC) | Polysaccharides of 15 types, conjugated to diphtheria toxin | IM |
Pneumococcal vaccine, conjugate (PCV20) (see Pneumococcal vaccine, conjugate (PCV20) (seeCDC) | Polysaccharides of 20 types, conjugated to diphtheria toxin | IM |
Pneumococcal vaccine, conjugate (PCV21) (see Pneumococcal vaccine, conjugate (PCV21) (seeCDC) | Polysaccharides of 21 types, conjugated to diphtheria toxin | IM |
Pneumococcal vaccine, polysaccharide (PPSV23) (see Pneumococcal vaccine, polysaccharide (PPSV23) (seeCDC) | Bacterial polysaccharides of 23 pneumococcal types | IM or subcutaneous |
Poliovirus vaccine, inactivated (IPV) (see CDC) | Inactivated viruses of all 3 serotypes | IM or subcutaneous |
Rabies vaccine (see Rabies vaccine (seeCDC) | Inactivated virus | Intradermal§ or IM |
Respiratory syncytial virus (RSV) vaccine (see CDC) | Recombinant viral glycoprotein antigen | IM |
Rotavirus vaccine (see Rotavirus vaccine (seeCDC) | Live virus | Oral |
Smallpox vaccine (see Smallpox vaccine (seeCDC) | Live vaccinia virus | Intradermal via multiple puncture device |
Tetanus toxoid (see CDC)¶ | Inactivated toxin (toxoid) | IM‡ |
Tick-borne encephalitis vaccine (see Tick-borne encephalitis vaccine (seeCDC) | Inactivated virus | IM |
Typhoid vaccine (ViCPS) (see Typhoid vaccine (ViCPS) (seeCDC) | Capsular polysaccharide | IM |
Typhoid vaccine (Ty21a) (see Typhoid vaccine (Ty21a) (seeCDC) | Live-attenuated vaccine | Oral |
Varicella virus vaccine (see CDC) | Live virus | Subcutaneous or IM |
Yellow fever vaccine (see Yellow fever vaccine (seeCDC) | Live virus | Subcutaneous |
Zoster vaccine (see Zoster vaccine (seeCDC) | Recombinant, adjuvanted | IM‡ |
* The list of vaccines included in this table is not exhaustive and is updated periodically. The types of vaccines available varies by country. | ||
† Tetanus-diphtheria contains the same amount of tetanus toxoid as diphtheria-tetanus-pertussis or diphtheria-tetanus but a reduced dose of diphtheria toxoid. | ||
‡ Preparations with adjuvants should be administered IM. | ||
§ Intradermal dose is lower and used only for preexposure vaccination. | ||
¶ A preparation with only tetanus toxoid (TT) is also available but is not recommended because periodic boosting is needed for both antigens. | ||
CDC = Centers for Disease Control and Prevention; IM = intramuscular; TT = tetanus toxoid; VLP = virus-like particle; WHO = World health Organization. | ||
The information here has been adapted from the Vaccine Recommendations of the Advisory Committee for Immunization Practices (ACIP). Accessed March 2025. | ||